Get the Stockscreener App
13.61
3.34%
0.44
Pre-market:
13.99
0.38
+2.79%
Dyne Therapeutics Inc stock is traded at $13.61, with a volume of 1.73M.
It is up +3.34% in the last 24 hours and down -4.29% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$13.17
Open:
$13.1
24h Volume:
1.73M
Relative Volume:
1.04
Market Cap:
$1.54B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-3.823
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
-2.86%
1M Performance:
-4.29%
6M Performance:
-70.47%
1Y Performance:
-49.41%
1-Day Range:
$12.87
$13.67
1-Week Range:
$12.87
$14.45
52-Week Range:
$12.87
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
13.61 | 1.54B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital - Defense World
Piper Sandler Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $48.00 - Defense World
HC Wainwright Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - Defense World
Rhumbline Advisers Boosts Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
HC Wainwright Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00 - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 2,598 Shares of Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month LowWhat's Next? - MarketBeat
Dyne Therapeutics stock target cut to $46 at H.C. Wainwright By Investing.com - Investing.com Canada
Dyne Therapeutics price target lowered to $48 from $53 at Piper Sandler - TipRanks
Buy Rating for Dyne Therapeutics: Promising Accelerated Approval Potential for DYNE-101 and DYNE-251 - TipRanks
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Dyne Therapeutics Advances Clinical Programs Amid Financial Losses - TipRanks
Dyne Therapeutics (DYN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise -February 27, 2025 at 09:42 am EST - Marketscreener.com
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
DYNE THERAPEUTICS Earnings Results: $DYN Reports Quarterly Earnings - Nasdaq
Dyne Therapeutics, Inc. Q4 Loss Beats Estimates - Nasdaq
Can Dyne's $783M War Chest and Fast-Tracked DM1 Program Transform Muscle Disease Treatment? - StockTitan
Dyne Therapeutics, Inc. SEC 10-K Report - TradingView
How To Trade (DYN) - Stock Traders Daily
Dyne therapeutics chief scientific officer sells $36,242 in stock By Investing.com - Investing.com South Africa
Dyne therapeutics chief scientific officer sells $36,242 in stock - Investing.com India
Dyne Therapeutics CSO Sells Shares to Satisfy Tax Obligations - TradingView
First Week of April 17th Options Trading For Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Myotonic Dystrophy Pipeline Analysis 2024: FDA Approvals - openPR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc.(DYN) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics SVP Richard Scalzo sells $34,707 in stock - Investing.com India
Dyne Therapeutics Officer Sells Shares to Satisfy Tax Obligations - TradingView
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(DYN) Technical Data - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Sets New 52-Week LowWhat's Next? - MarketBeat
abrdn plc Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics to Present Key Data from DELIVER and ACHIEVE Clinical Trials at 2025 MDA Conference - Nasdaq
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific - The Bakersfield Californian
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - GlobeNewswire
Major Clinical Data Alert: Dyne's DMD and DM1 Trial Results Set for Exclusive MDA Conference Reveal - StockTitan
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) - Yahoo Finance
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5%Here's What Happened - MarketBeat
abrdn plc Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics To Present At Oppenheimer Healthcare Conference; Webcast At 4:00 PM ET - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Dyne Therapeutics (NASDAQ:DYN) Trading Up 7%Time to Buy? - MarketBeat
Dyne Therapeutics Shares Rise Premarket as DMD Study Gets FDA Nod -July 05, 2022 at 08:18 am EDT - Marketscreener.com
Jennison Associates LLC Sells 135,037 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):